BriaCell's Early-Stage Combination Study In Advanced Breast Cancer Starts Enrollment

BriaCell Therapeutics Corp BCTX has opened recruitment and enrollment of their collaborative clinical study with Incyte Corporation INCY.
The Phase 1/2a combination study will evaluate BriaCell's lead candidate, Bria-IMT, with Incyte's retifanlimab & epacadostat to treat advanced breast cancer.
BriaCell and Incyte had previously treated two patients under this Phase I/IIa combination study after the corporate collaboration commencement in April 2019.
Bria-IMT in heavily pretreated advanced breast cancer patients achieved 12 months of average overall survival benefit. The top responder achieved 21.4 months survival plus 100% resolution of an eye-bulging orbital tumor.
Price Action: BCTX shares are up 3.25% at $6.04 during the premarket session on the last check Wednesday.